Survival outcomes following autologous stem cell transplant with melphalan 140mg/m<sup>2</sup> versus 200mg/m<sup>2</sup> preparative regimens in patients with multiple myeloma-Reference-Cited by-同舟云学术

Survival outcomes following autologous stem cell transplant with melphalan 140mg/m² versus 200mg/m² preparative regimens in patients with multiple myeloma

Published:2023-05-18 Issue:7 Volume:64 Page:1315-1321
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Sharma Nidhi¹,Benson Evan²,Zhao Qiuhong¹,Nunnelee Jordan¹³,Cottini Francesca¹,Elder Patrick¹,Rosko Ashley¹,Bumma Naresh¹,Khan Abdullah¹,Umyarova Elvira¹,Devarakonda Srinivas¹,Efebera Yvonne A.¹⁴,Benson Don M.¹⁵

Affiliation:

1. Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

2. Pre-Medical Program, University of Dayton, Dayton, OH, USA

3. The Ohio State University College of Medicine, Columbus, OH, USA

4. Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

5. Bone Marrow Transplantation & Cellular Therapy, OhioHealth, Columbus, OH, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2023.2213366

Reference18 articles.

1. HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA

2. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma

3. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

4. A Phase I Dose-Escalation Trial of High-Dose Melphalan with Palifermin for Cytoprotection Followed by Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Normal Renal Function

5. A randomized study of melphalan 200 mg/m2 vs 280 mg/m2 as a preparative regimen for patients with multiple myeloma undergoing auto-SCT